The Tumor Immune Microenvironment in Primary CNS Neoplasms: A Review of Current Knowledge and Therapeutic Approaches
Open Access
- 19 January 2023
- journal article
- review article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (3) , 2020
Abstract
Primary CNS neoplasms are responsible for considerable mortality and morbidity, and many therapies directed at primary brain tumors have proven unsuccessful despite their success in preclinical studies. Recently, the tumor immune microenvironment has emerged as a critical aspect of primary CNS neoplasms that may affect their malignancy, prognosis, and response to therapy across patients and tumor grades. This review covers the tumor microenvironment of various primary CNS neoplasms, with a focus on glioblastoma and meningioma. Additionally, current therapeutic strategies based on elements of the tumor microenvironment, including checkpoint inhibitor therapy and immunotherapeutic vaccines, are discussed.Keywords
This publication has 266 references indexed in Scilit:
- Association between Inflammatory Infiltrates and Isolated Monosomy 22/del(22q) in MeningiomasPLOS ONE, 2013
- Evaluation of mast cells and hypoxia inducible factor-1 expression in meningiomas of various grades in correlation with peritumoral brain edemaJournal of Neuro-Oncology, 2013
- Immune genes are associated with human glioblastoma pathology and patient survivalBMC Medical Genomics, 2012
- Hypoxia Potentiates Glioma-Mediated ImmunosuppressionPLOS ONE, 2011
- Tumor-infiltrating, myeloid-derived suppressor cells inhibit T cell activity by nitric oxide production in an intracranial rat glioma + vaccination modelJournal of Neuroimmunology, 2010
- Systemic immune suppression in glioblastoma: the interplay between CD14+HLA-DRlo/neg monocytes, tumor factors, and dexamethasoneNeuro-Oncology, 2010
- Polarization of Tumor-Associated Neutrophil Phenotype by TGF-β: “N1” versus “N2” TANCancer Cell, 2009
- Characterization and immunotherapeutic potential of γδ T-cells in patients with glioblastomaNeuro-Oncology, 2009
- Inhibiting TGF-β signaling restores immune surveillance in the SMA-560 glioma modelNeuro-Oncology, 2007
- CNS immune privilege: hiding in plain sightImmunological Reviews, 2006